1.24
1.24 (0%)
As of Apr 17, 2025
Taysha Gene Therapies, Inc. [TSHA]
Source:
Company Overview
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS.
| Country | United States |
| Headquarters | dallas, texas |
| Phone Number | ( 214 ) 612-0000 |
| Industry | manufacturing |
| CEO | Sean Nolan |
| Website | www.tayshagtx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $8.3 |
| Operating Profit | $-91.5 |
| Net Income | $-89.3 |
| Net Cash | $-4.9 |
Profit Ratios
| Gross Margin | $8.3 |
| Operating Margin | -1,097.6 |
| Profit as % of Revenues | -9.3% |
| Profit as % of Assets | -53.6% |
| Profit as % of Stockholder Equity | -124.9% |
Management Effectiveness
| Return on Equity | -124.9% |
| Return on Assets | -55.7% |
| Turnover Ratio | 5% |
| EBITA | $-91.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $160.4 |
| Total Liabilities | $88.8 |
| Operating Cash Flow | $-81.2 |
| Investing Cash Flow | $-0.4 |
| Financing Cash Flow | $76.7 |
